DCR-HBVS
Chronic Hepatitis B Virus Infection
PreclinicalCollaboration Terminated (Roche)
Key Facts
Indication
Chronic Hepatitis B Virus Infection
Phase
Preclinical
Status
Collaboration Terminated (Roche)
Company
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals established itself as a leader in next-generation RNAi therapeutics through its proprietary, liver-targeted GalXC™ and GalXC-Plus™ technology platforms. The company advanced a promising pipeline, most notably nedosiran for primary hyperoxaluria, and forged significant partnerships with industry leaders like Novo Nordisk, Roche, and Eli Lilly. Its successful trajectory culminated in a strategic acquisition by Novo Nordisk in December 2021, integrating Dicerna's platform to expand the acquirer's capabilities in genetic medicine for cardiometabolic and rare diseases.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Virus Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| ISA104 | ISA Pharmaceuticals | Phase 1/2a |
| ALN-HBV02 (VIR-2218) | Alnylam Pharmaceuticals | Phase 2 |